NCT02637193View on ClinicalTrials.gov

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Healthy Subjects
Interventions
DRUG

Venlafaxine

Multiple doses of Venlafaxine for 14 days plus 3 days of down titration

DRUG

Moxifloxacin

400 mg single dose moxifloxacin

DRUG

Drug - placebo

Placebo administered for 16 days

Trial Locations (1)

06511

Pfizer New Haven Clinical Research Unit, New Haven

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT02637193 - A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects | Biotech Hunter | Biotech Hunter